Table 1.
Therapeutic strategies that attenuate CV calcification in non-transgenic animal CKD models.
| Treatment | Substance | Dosis | Medication | Experimental Model | Species, Strain | Ref. |
|---|---|---|---|---|---|---|
| Phosphate binder | Sevelamer | 750 mg/kg | Daily oral gavage, 4 weeks |
Adenine diet | Wistar rat | [32] |
| Phosphate binder | Sevelamer | 3% | Diet, 6 months |
5/6 nephrectomy | Sprague-Dawley rat | [31] |
| Phosphate binder | CaMg | 185 mg/kg | Daily oral gavage, 6 weeks |
Adenine diet | Wistar rat | [33] |
| Calcimimetic | Cinacalcet | 10 mg/kg | Daily oral gavage, 12 weeks |
Adenine diet | Wistar rat | [38] |
CaMg: acetate/magnesium carbonate; Ref: Reference.